Groupama Asset Managment Raises Position in Illumina, Inc. $ILMN

Key Points

• Groupama Asset Management increased its stake in Illumina, Inc. by 139.0% in Q1, acquiring an additional 7,062 shares, bringing their total to 12,144 shares valued at $972,000.
• Illumina's earnings per share for the last quarter was $1.19, exceeding analysts' expectations of $1.02, although revenue was down 4.8% year-over-year.
• Recent price targets for Illumina's stock have varied, with Guggenheim lowering its target from $122.00 to $114.00, while Morgan Stanley raised its target from $100.00 to $105.00.

Groupama Asset Managment increased its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 139.0% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 12,144 shares of the life sciences company's stock after acquiring an additional 7,062 shares during the period. Groupama Asset Managment's holdings in Illumina were worth $972,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of ILMN. Vanguard Group Inc. lifted its holdings in Illumina by 3.5% during the 1st quarter. Vanguard Group Inc. now owns 16,371,662 shares of the life sciences company's stock worth $1,298,928,000 after buying an additional 558,243 shares during the period. WCM Investment Management LLC lifted its holdings in Illumina by 1.2% during the 1st quarter. WCM Investment Management LLC now owns 4,179,011 shares of the life sciences company's stock worth $334,321,000 after buying an additional 49,156 shares during the period. Brown Advisory Inc. lifted its holdings in Illumina by 52.1% during the 1st quarter. Brown Advisory Inc. now owns 2,909,228 shares of the life sciences company's stock worth $230,818,000 after buying an additional 996,589 shares during the period. Northern Trust Corp lifted its holdings in Illumina by 26.9% during the 4th quarter. Northern Trust Corp now owns 1,652,935 shares of the life sciences company's stock worth $220,882,000 after buying an additional 349,878 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Illumina by 2.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,292,407 shares of the life sciences company's stock worth $172,704,000 after buying an additional 32,270 shares during the period. Institutional investors own 89.42% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on ILMN shares. Morgan Stanley boosted their price objective on Illumina from $100.00 to $105.00 and gave the company an "equal weight" rating in a research note on Monday, August 4th. Guggenheim dropped their price target on Illumina from $122.00 to $114.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Canaccord Genuity Group upped their price target on Illumina from $99.00 to $105.00 and gave the stock a "hold" rating in a research note on Friday, August 1st. Piper Sandler dropped their price target on Illumina from $190.00 to $185.00 and set an "overweight" rating on the stock in a research note on Thursday, May 15th. Finally, Citigroup downgraded Illumina from a "hold" rating to a "strong sell" rating and dropped their price target for the stock from $85.00 to $80.00 in a research note on Wednesday, July 9th. Seven analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $124.58.

Illumina Stock Performance

Shares of ILMN stock traded up $2.51 during trading on Friday, hitting $101.80. The company's stock had a trading volume of 1,964,101 shares, compared to its average volume of 1,883,205. The company has a market cap of $15.65 billion, a PE ratio of 12.89, a P/E/G ratio of 2.29 and a beta of 1.37. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The business has a fifty day moving average of $98.18 and a 200-day moving average of $88.88. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The company had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same period in the prior year, the company posted $0.36 earnings per share. Illumina's quarterly revenue was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.